DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on Radio-DARPins now expanded to ten programsMP0533 Phase 1/2 ...
Project Optimus seeks to transform how doses are selected and optimised in oncology drug development. As this initiative ...
Mind Medicine (MindMed) Inc. ( NASDAQ: MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin - CMO ...
In the medical device industry, usability plays a critical role in ensuring the safety and effectiveness of highly complex ...
Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...
Promising multiple dose PK data continue to support 4-weekly dosingFDA advice received supporting phase 2 design in HSStrong Key Opinion ...
A new study reveals concerning risks associated with tattoos, including higher rates of lymphoma and skin cancer.
On November 5, 2024, Adial announced the appointment of Vinay Shah as the Company’s Chief Financial Officer. Mr. Shah is an accomplished Chief Financial Officer with over 25 years of experience in the ...
Health Affairs' Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women's Hospital and Harvard University on ...
FORWARD-53 is an ongoing Phase 2 open-label trial of WVE-N531. Muscle biopsies are taken after 24 and 48 weeks of dosing. The ...
A team of Yale researchers recently published promising results from a clinical trial testing the effectiveness of a new ...
Karen Winkfield, MD, PhD, addresses the importance of inclusive clinical trial participation and meeting patients where they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback